NJ Bio, Inc. and Ajinomoto Bio-Pharma Services have announced a collaboration aimed at expanding access to advanced antibody-drug conjugate (ADC) technologies for biopharma innovators. Under the agreement, NJ Bio will integrate Ajinomoto’s proprietary AJICAP™ site-specific conjugation platform into its discovery and early development workflows. The partnership is expected to enhance NJ Bio’s capabilities in antibody conjugation and linker technologies, enabling more precise and reproducible development of targeted therapeutics.
NJ Bio believes this technology could address a critical gap in novel site-specific conjugation, spanning ADCs, AOCs and other complex bioconjugates. It offers a scalable conjugation approach without relying on expensive microbial enzymes or column chromatography. AJICAP™ allows for site-specific modification of antibodies without requiring engineering, helping preserve structural integrity while improving pharmacokinetics and therapeutic performance. By incorporating this platform, NJ Bio aims to offer clients a more efficient path from early drug discovery through preclinical development.
The collaboration brings together NJ Bio’s expertise in medicinal chemistry, bioconjugation, and biologics with Ajinomoto’s scalable conjugation technology. Together, the companies expect to reduce development risk, accelerate timelines, and improve outcomes for next-generation antibody-conjugate based therapies.
Read the full press release here: NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development